OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharma company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that CEO Dr Gary Jacob will deliver an oral presentation at the BIO International Convention in Boston, being held from June 16 to 19.
He will discuss the development of urcosimod, OKYO’s lead drug candidate for NCP, a severe, chronic condition with no current US Food and Drug Administration-approved therapy.